Sign Up Today and Learn More About Deep Genomics Stock
Invest in or calculate the value of your shares in Deep Genomics or other pre-IPO companies through EquityZen's platform.
Deep Genomics Stock (DEGE)
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.
About Deep Genomics Stock
Founded
2014
Total Funding
16.7M
Industries
Software, Artificial Intelligence, Data and Analytics
Deep Genomics Press Mentions
Stay in the know about the latest news on Deep Genomics
Machine Learning in Pharmaceutical Industry Market Reach USD 26.2 Billion by 2031 Globally
einpresswire • Jun 25, 2025
Artificial Intelligence in Genomics: Revolutionizing Healthcare Through Data-Driven Insights
pharmiweb • Jun 21, 2025
Opinion: STAT+: Deep Genomics founder: Why AI for drug discovery will far exceed current expectations
statnews • Jun 21, 2025
Artificial Intelligence (AI) in Genomics Market expected to reach USD 44.63 Billion by 2032, with a growth of 50.1% CAGR
einpresswire • Jun 10, 2025
Systems and methods for classifying, prioritizing and interpreting genetic …
patents • May 04, 2025
Deep Genomics Management
Leadership team at Deep Genomics
Co-Founder
Hannes Bretschneider
Research Scientist & Engineer
Alice Gao
Join now and verify your accreditation status to gain access to:
- Deep Genomics Current Valuation
- Deep Genomics Stock Price
- Deep Genomics Management
- Available deals in Deep Genomics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Deep Genomics Cap Table and Funding History by Share Class and Liquidity Preferences
- Deep Genomics Revenue and Financials
- Deep Genomics Highlights
- Deep Genomics Business Model
- Deep Genomics Risk Factors
- Deep Genomics Research Report from SACRA Research
Trading Deep Genomics Stock
How to invest in Deep Genomics stock?
Accredited investors can buy pre-IPO stock in companies like Deep Genomics through EquityZen funds. These investments are made available by existing Deep Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Deep Genomics stock?
Shareholders can sell their Deep Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
